Feng Chi Biotech Corp.
Feng Chi Biotech Corp. engages in the wholesale and retail of medical equipment and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various geneti… Read more
Feng Chi Biotech Corp. (6744) - Total Liabilities
Latest total liabilities as of June 2025: NT$72.02 Million TWD
Based on the latest financial reports, Feng Chi Biotech Corp. (6744) has total liabilities worth NT$72.02 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Feng Chi Biotech Corp. - Total Liabilities Trend (2019–2024)
This chart illustrates how Feng Chi Biotech Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Feng Chi Biotech Corp. Competitors by Total Liabilities
The table below lists competitors of Feng Chi Biotech Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Accuracy Shipping Limited
NSE:ACCURACY
|
India | ₹1.83 Billion |
|
TERADYNE
MU:TEY
|
Germany | €867.19 Million |
|
Transition Metals Corp
PINK:TNTMF
|
USA | $333.24K |
|
WANdisco plc
PINK:WANSF
|
USA | $4.94 Million |
|
TJGC Group Limited
NASDAQ:TJGC
|
USA | $11.92 Million |
|
Lenox Pasifik Investama Tbk PT
JK:LPPS
|
Indonesia | Rp139.57 Million |
|
Mec Resources Ltd
AU:MMR
|
Australia | AU$437.22K |
|
Chaoprayamahanakorn Public Company Limited
BK:CMC
|
Thailand | ฿4.79 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Feng Chi Biotech Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Feng Chi Biotech Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Feng Chi Biotech Corp. (2019–2024)
The table below shows the annual total liabilities of Feng Chi Biotech Corp. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$59.19 Million | -6.10% |
| 2023-12-31 | NT$63.03 Million | -13.05% |
| 2022-12-31 | NT$72.49 Million | +29.03% |
| 2021-12-31 | NT$56.18 Million | -4.63% |
| 2020-12-31 | NT$58.91 Million | +9.55% |
| 2019-12-31 | NT$53.77 Million | -- |